These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 4859014

  • 41. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G, Casacchia M, Zamponi A, Agnoli A.
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract] [Full Text] [Related]

  • 42. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F, Gaillard JM, Eisenring JJ, Krassoievitch M, Yanniotis G, Tissot R.
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. [The L-dopa test in Parkinson's disease].
    Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y.
    Rev Neurol (Paris); 1985 Jan; 141(5):413-5. PubMed ID: 4048732
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J.
    Rev Neurol (Paris); 1970 Apr; 122(4):243-8. PubMed ID: 5472041
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C, Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C, Volante F.
    Z Neurol; 1972 Apr; 202(4):347-55. PubMed ID: 4117654
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ, Somerville B.
    Med J Aust; 1974 Mar 23; 1(12):429-32. PubMed ID: 4598384
    [No Abstract] [Full Text] [Related]

  • 55. [Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4-4602, amantadine)].
    Campanella G, Carrieri P, Romito D, Pasqual-Marsettin E.
    Acta Neurol (Napoli); 1973 Mar 23; 28(1):1-34. PubMed ID: 4704396
    [No Abstract] [Full Text] [Related]

  • 56. Plasma concentration of levodopa in patients with Parkinson's disease.
    Rinne UK, Sonninen V, Siirtola T.
    Eur Neurol; 1973 Mar 23; 10(5):301-10. PubMed ID: 4789106
    [No Abstract] [Full Text] [Related]

  • 57. [Substitution therapy of parkinsonism. Insufficient results with 3-0-methyldopa].
    Ajuriaguerra J, Gauthier G, Geissbuhler F, Simona B, Constantinidis J, Yanniotis G, Krassoievitch M, Eisenring J, Tissot R.
    Presse Med (1893); 1971 Jun 19; 79(30):1396. PubMed ID: 5093018
    [No Abstract] [Full Text] [Related]

  • 58. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F, Meerwaldt JD, Man in 't Veld AJ, Hovestadt A, Schalekamp MA.
    Ann Neurol; 1989 Jun 19; 25(6):624-8. PubMed ID: 2742363
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.